Navigation Links
Neurobiological Technologies Reports Third Quarter Fiscal 2009 Financial Results
Date:5/8/2009

igational drug which has recently completed a Phase 3 trial for brain swelling.

NOTE: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including risks relating to our terminated clinical trials, our remaining contractual commitments, the success of our efforts to maximize the value of our cash and other assets for our shareholders, and levels of future operations and expenditures, as well as other risks detailed from time to time in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release and we undertake no obligation to update these forward-looking statements.

                               CONDENSED STATEMENTS OF OPERATIONS
                      (Unaudited - in thousands, except per share amounts)


                               Three months ended       Nine months ended
                                    March 31,                March 31,
                                2009        2008         2009        2008

     REVENUES
         Royalty                1,505       2,161        5,590        6,245
         Technology sale
          and collaboration
          services              1,508       1,523        4,479        5,002

     Total revenues             3,013       3,684       10,069       11,247

     EXPENSES
         Research and
          development           1,857       5,945       17,701       18,822
         General and
          administrative        1,438       1,757        3,970        5,327

           Total expenses       3,295       7,702       21,671       24,149

     Operating los
'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEO
2. Neurobiological Technologies Reports Second Quarter Financial Results
3. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
4. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
5. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
6. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
7. Neurobiological Technologies Reports Going Concern Qualification
8. Steven H. Kane Appointed as President and Chief Executive Officer of Patient Safety Technologies, Inc.
9. Global Med Technologies(R), Inc. to Report First Quarter Financial Results on Friday, May 15, 2009
10. EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results
11. Greenway Medical Technologies PrimeSuite Solution Provides OB/GYN Physicians With Instant Access to Labor and Delivery Information at Point-of-Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 2015 At Natural Products Expo ... the launch of its powerful, location-aware iOS app ... sustainable products at any retailer that carries those ... Expo West Booth 6054. , Makeena’s proprietary ... non-GMO, organic, Paleo, and vegan, among many other ...
(Date:3/6/2015)... La (PRWEB) March 06, 2015 Many ... function despite medical therapy. If you (or someone you ... to knee osteoarthritis, you may be interested in the ... Covington Orthopedic announced today that he is one of ... Cytori Therapeutics to begin enrolling subjects as part of ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 In a new ... Polish mesothelioma patients reported that shoulder pain was their first ... on its website. Click here to read it now. ... analyzed the medical records of 49 mesothelioma patients ... reported that it was shoulder pain that first prompted them ...
(Date:3/6/2015)... 06, 2015 Los Angeles cosmetic dentist ... for Zoom whitening. Zoom is a special type of teeth ... Unlike other teeth whitening treatments, Zoom does its job in ... stains. For a limited time, Dr. Ghasri is offering Zoom ... usual price of $650 and allows patients to try out ...
(Date:3/6/2015)... As the Mayo Clinic's 2012 published Benicar ... Associates Nationwide Legal Services, A.P.C., comments on these findings ... v. Daiichi Sankyo, Inc., Case No. 3:15-cv-159, in US ... light of a recently filed lawsuit, Ford & Associates ... explore the Mayo Clinic's Benicar case study findings purportedly ...
Breaking Medicine News(10 mins):Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 3Health News:Kevin Darr, M.D. is Now Enrolling Patients in a New FDA-Approved Clinical Trial Evaluating Adipose-Derived Regenerative Cells in the Treatment of Knee Osteoarthritis 2Health News:New Report Reveals Shoulder Pain Could Signal Early Mesothelioma, According to Surviving Mesothelioma 2Health News:Los Angeles Cosmetic Dentist, Dr. Poneh Ghasri, is Now Offering a Promotion on Zoom Whitening 2Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 2Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 3Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 4
... Mylan Pharmaceuticals Inc. has received final approval from the ... Abbreviated New Drug Application (ANDA) for Fluoxetine Capsules ... generic version of Eli Lilly and Company's Prozac(R) Capsules. ... for the 12 months ending March 31, 2007, for ...
... set high staffing standards for elder care in nursing homes ... staff nurses to prevent serious safety violations, according to ... of Nursing. ,The majority of the nation's elderly ... is well below national recommendations for safe care, the study ...
... ocean measurements and by analysing climate simulations we can see ... be explained by natural variability',said CSIRO oceanographer Dr Gael Alory. ... to changes in the heat structure of the atmosphere and ... sub-tropical Indian Ocean of around two degrees celsius. ...
... brand ambassadors of India. But they could also prove a ... case of Thirumurthy Nakka Boomaiah , 35 and hailing ... ,He has been sentenced to 69 days in ... London to Philadelphia and assaulting flight attendants. But he has ...
... during pregnancy could be harmful, according to an Iranian university ... anemia in pregnancy but many women take extra iron. Anemia ... enough oxygen due to low number of red blood cells ... normal amounts of oxygen. Common symptoms of anemia include feeling ...
... who were treated at Presbyterian Hospital of Dallas for ... the hospital and doctors there took part in a ... women's problems. ,According to the complaint filed ... a patient in Presbyterian's Eating Disorder Program. There, psychiatrist ...
Cached Medicine News:Health News:Policy Changes Have Direct Effect on Nursing Home Care 2Health News:Policy Changes Have Direct Effect on Nursing Home Care 3Health News:Climate Change Signal Detected in the Indian Ocean 2Health News:Indian Engineer Sentenced for Groping Women During Flight 2Health News:Anorexia Patients Sue Dallas' Presbyterian Hospital 2
(Date:3/6/2015)...  AbbVie (NYSE: ABBV ) will participate ... March 12, 2015. Richard A. Gonzalez , chairman ... and answer session at 8:30 a.m. Central time. ... be accessible through AbbVie,s Investor Relations Web site at ... will be available later that day. ...
(Date:3/6/2015)... Alemania, 6 de marzo de 2015 ... de gestión empresarial de imagen médica, fortalece su ... nombramiento de Randolph Sternberg como director ... como director de operaciones. Logo - ... será responsable de las ventas y desarrollo ...
(Date:3/5/2015)... 5, 2015   MeridianRx earned highest ... seven optional leading indicators during its recent URAC ... "We are very proud of earning this level ... , Chief Operating Officer of MeridianRx. "It is ... to transparency, flexibility and innovation." URAC,s ...
Breaking Medicine Technology:TeraRecon fortalece su posición en EMEA 2TeraRecon fortalece su posición en EMEA 3MeridianRx Earns Highest URAC Accreditation Status 2
... May 4 With today,s announcement of a new ... leadership in health information technology (HIT) has now attracted $49.5 ... Reinvestment Act (ARRA). , , ... The latest grant comes through the Beacon Communities Cooperative Agreement ...
... NEW ORLEANS , May 4 ... with Traficet-EN™ (CCX282-B) in the Maintenance period of PROTECT-1 ...   Traficet-EN maintained a clinical remission rate (Crohn,s Disease ... in Crohn,s patients over the course of 36 weeks, ...
Cached Medicine Technology:Total Federal Grant Funds for Indiana Health Information Technology Efforts Climb to Nearly $50 Million; Latest $16 Million Installment Spotlights Indiana Health Information Exchange in Delivering Higher Quality and Higher Value Healthcare Through M 2Total Federal Grant Funds for Indiana Health Information Technology Efforts Climb to Nearly $50 Million; Latest $16 Million Installment Spotlights Indiana Health Information Exchange in Delivering Higher Quality and Higher Value Healthcare Through M 3Total Federal Grant Funds for Indiana Health Information Technology Efforts Climb to Nearly $50 Million; Latest $16 Million Installment Spotlights Indiana Health Information Exchange in Delivering Higher Quality and Higher Value Healthcare Through M 4ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference 2ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference 3ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference 4ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference 5ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference 6
... Proven ergonomic design reduces hand fatigue, prevents injury. Dry seal technology. No ... 0.2-2 Inaccuracy (%) ... Imprecision(%) ... 0.01 Dimensions: ...
... improved ergonomics for today's exacting laboratory ... finger rest and the large display ... Finnpipette Digitals also feature soft-touch tip ... pend.) and super blow-out for 0.2 ...
... Pipetman Ultra is a fully adjustable, air-displacement ... It is the latest member of the ... characteristics: robustness, accuracy, and precision. We also ... feedback from our customers. Eight models cover ...
Developed specifically for the 5000/5500 ultrasound consoles....
Medicine Products: